Target Group Q3: Going-Concern Warning, Loan Defaults as Revenue Jumps to $2.0M
CBDY sits 80% above its 52-week low of $0.001.
Summary
Target Group's Q3 2026 filing discloses substantial doubt about its ability to continue as a going concern, a defaulted $2.2M shareholder loan and a defaulted related-party loan, offset by revenue that quadrupled year over year to $2.0M in the quarter.
Key Events · Earnings and Guidance · CBDY
-
Going-Concern Warning Disclosed
As of September 30, 2026, the company reports a working capital deficit of $11,317,427 and an accumulated deficit of $33,264,975, with only $181,129 of cash, raising substantial doubt about its ability to continue as a going concern.
-
Shareholder Loan in Default
The first five tranches of the secured Jerry Zarcone shareholder loan matured August 31, 2026 and remain unpaid, with about $2,196,424 of principal outstanding and roughly $3,053,886 in arrears including interest. The lender has committed not to enforce while an extension is negotiated, but no waiver or extension has been executed.
-
Revenue Quadrupled, Loss Narrowed
Q3 2026 revenue was $2,009,633 versus $499,650 a year earlier, and the quarterly net loss narrowed to $168,281 from $479,392. Nine-month revenue rose to $4,269,913 from $3,145,813, but the nine-month net loss widened to $958,449 from $807,375.
-
Lawsuit Settled for $281,920
Effective November 5, 2026, the company settled the former-employee lawsuit for $281,920 (CAD $400,000), payable in installments through May 6, 2027. An uncured payment default could trigger a consent judgment of up to $563,840 (CAD $800,000).
Analysis · CBDY · Life Sciences
An explicit going-concern warning sits atop Target Group's Q3 2026 report: a $11,317,427 working capital deficit and $33,264,975 accumulated deficit against just $181,129 of cash. The secured shareholder loan from Jerry Zarcone is in default — the first five tranches matured August 31, 2026 and remain unpaid, with roughly $3,053,886 in arrears including interest — and the related-party CLI loan is also in default and due on demand. While an extension is negotiated, the lender has promised not to enforce, but no waiver or extension has been signed. Against that backdrop, revenue is genuinely improving: Q3 revenue of $2,009,633 versus $499,650 a year earlier, and the quarterly net loss narrowed to $168,281 from $479,392. The nine-month loss still widened to $958,449 from $807,375, and interest and bank charges of $866,159 are consuming the gross profit. A November 5, 2026 settlement of the former-employee lawsuit for $281,920 (CAD $400,000) removes one overhang but adds a payment schedule through May 2027, with consent-judgment exposure up to $563,840 (CAD $800,000) if payments slip. Management also concluded disclosure controls were not effective.
How filings like this one have moved
In the 30 days to Nov 17, 2026, 48.3% of the 2133 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.28%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, CBDY was trading at $0.00 on OTC in the Life Sciences sector, with a market capitalization of approximately $555.3K. The 52-week trading range was $0.00 to $0.00. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.